<DOC>
	<DOCNO>NCT00292981</DOCNO>
	<brief_summary>Hereditary angioedema ( HAE ) rare disorder characterize congenital lack functional C1 esterase inhibitor . If treat adequately , acute attack HAE life-threatening may even result fatality , especially case involvement larynx.The plan extension study design enrol subject participate pivotal study order provide C1-INH treatment acute HAE attack 24 month licensing procedure C1-INH finalized , whatever come first .</brief_summary>
	<brief_title>C1 Esterase Inhibitor Hereditary Angioedema ( HAE ) ( Extension Study )</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>Key Documented congenital C1INH deficiency Acute HAE attack Participation base study CE1145_3001 ( NCT00168103 ) Key Acquired angioedema Treatment investigational drug besides CE1145 last 30 day study entry</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>C1 Inhibitor</keyword>
	<keyword>Hereditary angioedema</keyword>
	<keyword>Acute HAE attack</keyword>
</DOC>